Monthly Archives: March 2013
Industry Insight – TGA Blueprint
Regardless of the type of therapeutic good you commercialise – original brand medicine, generic medicine, biological or medical device – we all share the common challenge of operating in a heavily regulated market. Therefore the role of the TGA in approving these products for market entry and maintaining marketability is paramount for commercial success in the pharmaceutical and medical device industry. In this Industry Insight we see how the TGA’s Blueprint reforms stack up and look at the impact on industry. Continue reading
People Trends – Turnover at the top reflects industry broadly
In a media release last month, Medicines Australia announced the resignation of its Board Chair, Mark Masterson. When we consider the recent turnover of MA board members does this turnover at the top reflect what is going on in the industry more broadly? Continue reading
Election Watch 2013
In January, the Prime Minister stated she was “not starting the nation’s longest election campaign.” What she has started however, is a very long period of political lobbying from the pharmaceutical and healthcare industry. Continue reading
Top 5 – Hot Topics Affecting Industry
Commercial Eyes holds a unique place as trusted advisers in the Australian pharmaceutical and medical device industries. We are often asked for advice in navigating the market forces that affect how our clients conduct their businesses. So, here are the top 5 hot topics our clients are seeking advice on in 2013. Continue reading
